{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:05:16Z","timestamp":1788973516562,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"China Cardiovascular Association-Cardiac Rehabilitation and Metabolic Therapy research fund","award":["No. CCA-CRMT-1712"],"award-info":[{"award-number":["No. CCA-CRMT-1712"]}]},{"name":"Young Talents Project of Medical and Health Research in Zhejiang Province","award":["No. 2019RC188"],"award-info":[{"award-number":["No. 2019RC188"]}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY18H020007"],"award-info":[{"award-number":["LY18H020007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Trimetazidine is a metabolic anti-ischemic agent, which increases the tolerance of cardiomyocytes to ischemia. However, few studies have explored the effect of trimetazidine on ventricular remodeling in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) with left ventricular hypertrophy (LVH).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>It is a randomized, placebo-controlled trial, and we propose to recruit one hundred and twenty-four CAD patients undergoing PCI with LVH during a 12-month period. They will be randomized to receive either trimetazidine (35\u2009mg twice a day) or placebo in the following 12\u2009months after PCI. Blood tests, echocardiography, symptom of angina and major adverse cardiovascular events (MACEs) will be collected at follow-up visit at 3 and 12\u2009months. The primary end point will be the left ventricular remodeling measured by left ventricular mass index (LVMI) at 3- and 12-month follow-up compared with the baseline. The secondary end points will be the symptom of angina assessed by Seattle Angina Questionnaire, myocardial ischemia measured by 6-min walk test and exercise electrocardiography test, as well as MACEs (defined as a composite of death, myocardial infarction, stroke, recurrent angina, re-hospitalization, change of viable myocardium).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>This study aims to demonstrate the effect of trimetazidine on left ventricular remodeling and myocardial ischemia in CAD patients undergoing PCI with LVH. Trimetazidine treatment is likely to improve the left ventricular remodeling, symptoms of angina and myocardial ischemia. It might also reduce the risk of MACEs in CAD patients undergoing PCI with LVH.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>http:\/\/www.chictr.org.cn, Chinese Clinical Trial Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=29835\">ChiCTR1800017876<\/jats:ext-link>). Registered on 19 Aug 2018.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-020-01557-3","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:02:50Z","timestamp":1591383770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Lili","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4746-9570","authenticated-orcid":false,"given":"Wenbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"3","key":"1557_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2215\/CJN.03871106","volume":"2","author":"PA McCullough","year":"2007","unstructured":"McCullough PA. Coronary artery disease. Clin J Am Soc Nephrol. 2007;2(3):611\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1557_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/CRD.0b013e3182532286","volume":"20","author":"S Narasimhan","year":"2012","unstructured":"Narasimhan S, McKay K, Bainey KR. Coronary artery disease in south Asians. Cardiol Rev. 2012;20(6):304\u201311.","journal-title":"Cardiol Rev"},{"issue":"Suppl 1","key":"1557_CR3","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/00005344-199306221-00003","volume":"22","author":"FH Messerli","year":"1993","unstructured":"Messerli FH, Ketelhut R. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor. J Cardiovasc Pharmacol. 1993;22(Suppl 1):S7\u201313.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1557_CR4","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4081\/hi.2009.e9","volume":"4","author":"DL Brown","year":"2009","unstructured":"Brown DL. Effect of left ventricular hypertrophy on long-term survival of patients with coronary artery disease following percutaneous coronary intervention. Heart Int. 2009;4(1):e9.","journal-title":"Heart Int"},{"issue":"3","key":"1557_CR5","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.ejrad.2011.01.088","volume":"81","author":"LA Malek","year":"2012","unstructured":"Malek LA, Spiewak M, Klopotowski M, Petryka J, Mazurkiewicz L, Kruk M, et al. Influence of left ventricular hypertrophy on infarct size and left ventricular ejection fraction in ST-elevation myocardial infarction. Eur J Radiol. 2012;81(3):e177\u201381.","journal-title":"Eur J Radiol"},{"key":"1557_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.116.004823","volume":"6","author":"L Nepper-Christensen","year":"2017","unstructured":"Nepper-Christensen L, L\u00f8nborg J, Ahtarovski KA, H\u00f8fsten DE, Kyhl K, Ghotbi AA, et al. Left ventricular hypertrophy is associated with increased infarct size and decreased myocardial salvage in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc. 2017;6:1.","journal-title":"J Am Heart Assoc"},{"key":"1557_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245\u201362.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"1557_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.yexcr.2017.03.052","volume":"360","author":"T Tuomainen","year":"2017","unstructured":"Tuomainen T, Tavi P. The role of cardiac energy metabolism in cardiac hypertrophy and failure. Exp Cell Res. 2017;360(1):12\u20138.","journal-title":"Exp Cell Res"},{"issue":"11","key":"1557_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa025050","volume":"349","author":"F Cecchi","year":"2003","unstructured":"Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"1557_CR10","first-page":"533","volume":"29","author":"H Szwed","year":"2000","unstructured":"Szwed H, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med. 2000;29(10):533\u20138.","journal-title":"Presse Med"},{"issue":"24","key":"1557_CR11","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","volume":"22","author":"H Szwed","year":"2001","unstructured":"Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267\u201374.","journal-title":"Eur Heart J"},{"issue":"2","key":"1557_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ijcard.2012.11.001","volume":"168","author":"C Vitale","year":"2013","unstructured":"Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol. 2013;168(2):1078\u201381.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1557_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","volume":"86","author":"PF Kantor","year":"2000","unstructured":"Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2000;86(5):580\u20138.","journal-title":"Circ Res"},{"issue":"6","key":"1557_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000139070","volume":"46","author":"C Guarnieri","year":"1993","unstructured":"Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology. 1993;46(6):324\u201331.","journal-title":"Pharmacology."},{"issue":"4","key":"1557_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0008-6363(00)00161-9","volume":"47","author":"HR Cross","year":"2000","unstructured":"Cross HR. Trimetazidine: a novel protective role via maintenance of Na (+)\/K (+)-ATPase activity? Cardiovasc Res. 2000;47(4):637\u20139.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1557_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ehj.2004.02.018","volume":"25","author":"L Lee","year":"2004","unstructured":"Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25(8):634\u201341.","journal-title":"Eur Heart J"},{"issue":"Suppl 4","key":"1557_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/BF00051282","volume":"4","author":"C Guarnieri","year":"1990","unstructured":"Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle. Cardiovasc Drugs Ther. 1990;4(Suppl 4):814\u20135.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"1557_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0008-6363(00)00136-X","volume":"47","author":"H El Banani","year":"2000","unstructured":"El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res. 2000;47(4):688\u201396.","journal-title":"Cardiovasc Res"},{"issue":"Suppl 5","key":"1557_CR19","first-page":"V31","volume":"19","author":"F Beygui","year":"2000","unstructured":"Beygui F. Trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Rev Port Cardiol. 2000;19(Suppl 5):V31\u20134.","journal-title":"Rev Port Cardiol"},{"issue":"2","key":"1557_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00129784-200707020-00006","volume":"7","author":"A Labrou","year":"2007","unstructured":"Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2007;7(2):143\u201350.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"1557_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"1557_CR22","first-page":"919","volume":"132","author":"GH Guyatt","year":"1985","unstructured":"Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919\u201323.","journal-title":"Can Med Assoc J"},{"issue":"3","key":"1557_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000441276","volume":"133","author":"YS Hamirani","year":"2016","unstructured":"Hamirani YS, Kundu BK, Zhong M, McBride A, Li Y, Davogustto GE, et al. Noninvasive detection of early metabolic left ventricular remodeling in systemic hypertension. Cardiology. 2016;133(3):157\u201362.","journal-title":"Cardiology."},{"issue":"2","key":"1557_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","volume":"15","author":"R Ferrari","year":"2018","unstructured":"Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, et al. Expert consensus document: a \u2018diamond\u2019 approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120\u201332.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"1557_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4070\/kcj.2013.43.7.462","volume":"43","author":"S Demirelli","year":"2013","unstructured":"Demirelli S, Karakelleoglu S, Gundogdu F, Tas MH, Kaya A, Duman H, et al. The impact of Trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J. 2013;43(7):462\u20137.","journal-title":"Korean Circ J"},{"issue":"4","key":"1557_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40261-014-0170-9","volume":"34","author":"X Xu","year":"2014","unstructured":"Xu X, Zhang W, Zhou Y, Zhao Y, Liu Y, Shi D, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-Centre, prospective, randomized, double-blind study at 2-year follow-up. Clin Drug Investig. 2014;34(4):251\u20138.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1557_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12872-016-0399-8","volume":"16","author":"A Chen","year":"2016","unstructured":"Chen A, Li W, Chen X, Shen Y, Dai W, Dong Q, et al. Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction. BMC Cardiovasc Disord. 2016;16(1):225.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1557_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/cvr\/cvq181","volume":"88","author":"X Liu","year":"2010","unstructured":"Liu X, Gai Y, Liu F, Gao W, Zhang Y, Xu M, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res. 2010;88(1):150\u20138.","journal-title":"Cardiovasc Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01557-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01557-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:25:19Z","timestamp":1622849119000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01557-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01557-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"16 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Sir Run Run Shaw Hospital of Zhejiang University (KY20180508\u201325) and complied with the declaration of Helsinki. Written informed consent to participate will be obtained from each patient before enrollment in the study. This study has been registered in Chinese Clinical Trial Registry (; ChiCTR1800017876) on 19 Aug 2018. The study\u2019s recruitment is still ongoing and the recruitment time is from 2018-09-01 to 2020-12-31, which is also available on Chinese Clinical Trial Registry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents should be obtained from patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}